Moderna Agrees to $950 Million Settlement to End Global Patent Litigation
Cambridge, Tuesday, 3 March 2026.
In a significant move to clear its legal horizon, Moderna has agreed to pay $950 million to Arbutus Biopharma and Genevant Sciences, resolving worldwide disputes over the lipid nanoparticle technology used in its COVID-19 vaccines. While the deal eliminates future royalties, the total payout could swell by an additional $1.3 billion depending on the outcome of a federal appeal regarding government-contractor liability, potentially marking one of the largest patent settlements in pharmaceutical history.
Structuring the Billion-Dollar Accord
On March 3, 2026, Moderna (MRNA) announced a definitive agreement with Arbutus Biopharma and Genevant Sciences to resolve all outstanding patent litigation concerning the lipid nanoparticle (LNP) delivery systems critical to mRNA vaccines [1][5]. Under the terms of the settlement, Moderna is obligated to make an upfront cash payment of $950 million in July 2026 [2][3]. This payment effectively settles the commercial disputes between the entities and releases Moderna from any future royalty obligations regarding the disputed technology [1][5]. The agreement grants Moderna a global non-exclusive license for the LNP technology utilized in its infectious disease mRNA vaccines, securing the intellectual property foundations for its current and future product lines [2][4].
The Section 1498 Contingency
While the $950 million payment is fixed, the total value of the settlement contains a significant variable tied to government contracting law. The agreement includes a contingent payment of up to $1.3 billion, pending the outcome of Moderna’s appeal to the Federal Circuit Court of Appeals regarding Section 1498 of the U.S. Code [1][2]. This statute typically shields government contractors from patent infringement liability for goods manufactured for the U.S. government, shifting the liability instead to the government itself [4]. If the appellate court determines that Moderna is liable for doses provided to the government—ruling that Section 1498 does not bar the claims—Moderna will be required to pay the additional $1.3 billion within 90 days of that decision [1][5]. Conversely, if Moderna succeeds in its appeal, this additional liability would be nullified.
Financial Revisions and Market Impact
From an accounting standpoint, Moderna expects to record the $950 million charge in the first quarter of 2026 [1][5]. As a result of this significant outflow, the company has revised its financial guidance, projecting that its cash and cash equivalents will settle between $4.5 billion and $5.0 billion by the end of 2026 [1]. Despite the magnitude of the potential contingent payment, Moderna has stated that it considers a loss in the Section 1498 proceedings to be “not probable” and, accordingly, has not recorded an accrual for the potential $1.3 billion liability [1][5]. CEO Stéphane Bancel noted that resolving this “legacy matter” allows the company to direct its full focus toward its near-term future developments [1][5].
The Broader Intellectual Property Landscape
The settlement includes Moderna consenting to a judgment of infringement and “no invalidity” regarding four specific patents held by Genevant and Arbutus [2][3]. However, this agreement does not signal the end of all patent hostilities in the mRNA sector. Litigation involving Pfizer and BioNTech remains active in the United States [2]. A favorable Markman ruling—a key pre-trial decision defining the scope of patent claims—was issued in September 2025 in the ongoing litigation against Pfizer and BioNTech, whose Comirnaty vaccine represents approximately two-thirds of global COVID-19 mRNA vaccine sales [2][4]. While Moderna has successfully cleared a major legal hurdle with this $2.25 billion potential deal structure, the broader battle over the ownership of foundational mRNA technologies continues to evolve [3].